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Abstract
Introduction. Studies on expression of orexins (OXs) and their receptors in human prostate gland and human 
prostatic cell lines are scanty and their results contradictory. Regarding this, we carefully reinvestigated this 
problem on human prostatic cell lines.
Material and methods. Expression of preproorexin (ppOX) (6 primer pairs), and orexin receptors 1 and 2 (OXR1, 
OXR2) (4 and 2 primer pairs, respectively) was assessed by conventional PCR and QPCR in human normal 
(PrEC, PrSc, PrSmC) and prostate carcinoma (Du145, LNCaP, and PC3) cell lines. We designed intron spanning 
primers and also we applied primers from earlier publications and commercially available ones.
Results. With the designed primer pairs, in all studied cell lines we failed to demonstrate expression of ppOX, 
OXR1 and OXR2 genes at the mRNA level, while reaction products were observed in control tissues (human 
placenta and adrenals). Primers applied in earlier studies did not form amplification products specific for 
preproorexin or orexin 1 receptor. Some commercially available primers for orexin receptor 1 produced false 
positive results.
Conclusions. We found no evidence for the presence of preproorexin–orexin receptors system genes’ mRNAs 
in human prostate cell lines. The reported premises for these genes’ expression in prostate and prostatic cell 
lines may have arisen either from the presence of non-prostate cells included in the samples or from faulty PCR 
settings. (Folia Histochemica et Cytobiologica 2015, Vol. 53, No. 4, 333–341)
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Introduction
In 1998, two independent groups identified peptides 
in the rat hypothalamus involved in the stimulation 
of food intake [1–2]. De Lecea and co-workers [1] 
defined the proteins as hypocretins (HCRT), while 
Sakurai group [2] — as orexins (OXs). Orexin-A 
(OXA) corresponded to hypocretin-1 (HCRT1) 
and orexin-B (OXB) corresponded to hypocretin-2 
(HCRT2). Both OXs are produced during posttrans-
lational modification from common precursor prepro-
orexin (ppOX). They biological action is mediated 
through two specific G protein-coupled receptors 
(OXR). Orexin receptor 1 (OXR1) is highly selective 
for OXA, while orexin receptor 2 (OXR2) has affinity 
for both OXA and OXB peptides. 
Initially OXs and their receptors were identified 
in the CNS. Subsequently, OXs and OXRs have also 
been detected in a wide range of organs outside the 
CNS [3–8]. However, expression of OXs-OXRs sys-
tem and the mechanism of OXs action in peripheral 
tissues have not been completely clarified.
OXs and OXRs are also expressed in the male 
reproductive system and data are available among 
others for human, cattle, sheep and chicken [9–15]. 
However, expression of OXs and their receptors in 
human prostate gland is very controversial. In 2011 
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our group demonstrated on both mRNA and protein 
levels (Western blot and immunocytochemistry) low 
expression of OXR2 in normal human prostate and 
elevated expression of this gene in benign prostatic 
hyperplasia (BPH) but we were unable to demonstrate 
expression of ppOX and OXR1 in studied samples [16]. 
However, in 2013 expression of OXA and OXR1 in 
human prostate and expression of OXR1 in human 
normal prostate epithelium immortalized cell line 
(PNT1A) was reported [17]. Recently the same group 
has demonstrated in human prostate carcinoma (PC) 
expression of ppOX and OXR1 at the mRNA levels. 
Moreover, authors found in human androgen-de-
pendent prostate carcinoma cells LNCaP the presence 
of OXR1 mRNA, levels of which were elevated upon 
OXA addition to the culture medium [18]. Because 
of the discrepancy between these two observations 
we decided to carefully reinvestigate this problem on 
human prostatic cell lines.
Material and methods
Cell culture. The human prostate cell lines: prostate epithe-
lial cell (PrEC), prostate stromal cell (PrSc) and prostate 
smooth muscle cell (PrSmC) were purchased from Lonza 
(Walkersville, MD, USA). Each cell line was grown under 
specific conditions, including special medium in accordance 
with the recommendations of the seller. Prostate epithelial 
cells (PrEC) were grown in the Prostate Epithelial Cell 
Medium BulletkitTM (PrEGM) containing BPE (bovine 
pituitary extract), hydrocortisone, hEGF, epinephrine, 
transferrin, insulin, retinoic acid, triiodothyronine, GA-1000 
(gentamycin) (Lonza). Prostate stromal cells (PrSc) were 
grown in the Stromal Cell Medium BulletkitTM (SCGM) 
containing growth supplements: hFGF-B, insulin, FBS, 
GA-1000 (Lonza). Prostate smooth muscle cells (PrSmC) 
were grown in the Smooth Muscle Cell Medium BulletkitTM 
(SmGM-2) containing growth supplements: hEGF, insulin, 
hFGF-B, FBS and GA-1000 (Lonza). Prostate carcinoma 
cells (Du145, LNCaP, PC3) were purchased from ATCC 
(American Type Culture Collection, Manassas, Rockville, 
MD, USA). LNCaP and Du145 cells were grown in RPMI 
Medium 1640 (1X) + GlutaMAX + HEPES (Gibco, Life 
technologies, Carlsbad, CA, USA). PC-3 cells were grown 
in F-12K medium commercially available from ATCC 
(American Type Culture Collection). 
All cell lines were cultured in Falcon flasks in a humid-
ified incubator at 37°C and 5% CO2. After seeding on the 
first day, the culture medium was replaced with a new one 
and then changed every second day. All lines were cultured 
for 3–4 days but LNCaP cells for 7–8 days.
RNA isolation. Human prostate culture cells were washed 
two times using PBS, then the total RNA was extracted using 
TRI Reagent (Sigma-Aldrich, Poznan, Poland). Total RNA 
was purified on columns (NucleoSpin Total RNA Isolation, 
Qiagen GmbH, Hilden, Germany) [19–23]. The amount 
of total RNA was determined by optical density at 260 nm 
and its purity was estimated by 260/280 nm absorption ratio 
(higher than 1.8) (NanoDrop spectrophotometer, Thermo 
Scientific, Waltham, MA, USA). Data for positive samples 
were obtained from tissue homogenates (human placenta 
for ppOX and human adrenals for OXR1 and OXR2). Total 
RNA was extracted in a tissue homogenizer using also TRI 
Reagent (Sigma-Aldrich). Total RNA was also purified on 
columns (NucleoSpin Total RNA Isolation, Qiagen) in the 
same procedure as for prostate carcinoma cell lines RNA 
extraction.
Reverse transcription. Reverse transcription was performed 
using reverse transcriptase from Transcriptor First Strand 
cDNA Synthesis Kit (Roche) with Oligo(dT) (Roche Diag-
nostics Corporation, Indianapolis, IN, USA) as primers in 
the temperature of 55°C for 40 min (Thermocycler UNO II, 
Biometra, Göttingen, Germany). 1 μg of total RNA was 
used for a single RT reaction. The RTs were carried out in 
standard final volumes (20 μL). After RT each cDNA con-
taining sample was diluted with 100 μL of RNase-free water. 
QPCR. Primers were designed by Primer 3 software 
(Whitehead Institute for Biomedical Research, Cambridge, 
MA, USA) and purchased from the Laboratory of DNA 
Sequencing and Oligonucleotide Synthesis, Institute of 
Biochemistry and Biophysics, Polish Academy of Sciences, 
Warsaw (Table 1). 
The primer designed as PPH01112A for human 
HCRTR1 was purchased from SABiosciences (Qiagen).
QPCR was performed by means of the Lightcycler 2.0 
instrument (Roche, 4.05 software version). Using the above 
mentioned primers, SYBR green detection system was 
applied. Each of 20 μL reaction mixtures contained 4 μL 
template cDNA (standard or control), 0.5 μM of every 
gene-specific primer and a previously determined optimal 
MgCl2 concentration (3.5 μM for one reaction). According 
to the Roche LightCyclerFastStart DNA Master SYBR 
Green 1 Kit procedure for QPCR, 1–5 μL of the RT reaction 
product (cDNA) can be used in 20 μL or 50 μL final reaction 
volume. LightCyclerFastStart DNA Master SYBR Green I 
mix program (Roche) was used. The real-time PCR program 
included 10 min denaturation step to activate the Taq DNA 
Polymerase, followed by a three-step amplification program: 
denaturation at 95°C for 10 s, annealing at 56°C for 5 s, and 
extension at 72°C for 5 s. Assays were run for maximally 
45 cycles. Specificity of reaction products was checked by the 
determination of melting points (0.1°C/s transition rate). To 
determine the efficiency of target and reference reactions, 
standard curves for orexin and GAPDH were prepared with 
products of conventional RT-PCR. These products were 
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purified on Millipore columns and their concentrations 
were determined using the spectrophotometric method. 
PCR samples were mixed with TE-buffer and purified on 
columns. After spinning, pure product, which was diluted 
with TE-buffer, remained on the columns.
Standard curves were made for the following primers: 
GAPDH (human placenta and adrenal gland), OX, OXR1, 
OXR2. Using the Lightcycler software, we evaluated qPCR 
efficiency and R2 by performing a 10-fold dilution series 
experiment of the target assays. These data were obtained 
for selected primers (identified on agarose gel as a positive 
control) (Table 2). The limit of detection (LOD) was calcu-
lated by serial 10-fold standard curve dilution experiments. 
The lowest value of dilution given a specific PCR product 
was considered as LOD (Table 2).
GAPDH was used as a standard for controlling RT-PCR 
reaction quality as well as the reference gene in prostatic 
cell lines. The value of Cp for GAPDH gene expression 
was between 19–26 cycles (the lowest cycle for PrSMC, the 
highest for adrenal gland). In all experiments we used primer 
concentrations suggested by the Roche protocol.
Electrophoresis. QPCR samples were separated in a 2% 
agarose gel prepared with GelStar Nucleic Acid Gel Stain 
Table 1. Conventional RT-PCR and QPCR analyses of ppOX — human orexin neuropeptide precursor, OXR1 — human 
orexin receptor 1 and OXR2 — human orexin receptor 2
cDNA
(no. of primers)
Genebank  
Accession Number
Primer Primer sequence (5’-3’) Position PCR product 
size (bp)
ppOX (1) NM_001524.1 S
A
CATCTCCTTTCCCGGCTACC
GCCCAGGAGACCTTTGTGGA
47–66
100–119
73
ppOX (2) NM_001524.1 S
A
TTCCTTCCACAAAGGTCTCC
AGCAAGTCTTTTGACGACAGC
95–114
203–223
129
ppOX (3) NM_001524.1 S
A
ACAATTGACAGCCTCAAGGTTC
AGCAGCAGTAGCGTCACGG
2–23
122–140
139
ppOX (4) NM_001524.1 S
A
TCCACAAAGGTCTCCTGGGC
CAGCTCGTAGAGGCGGCAAG
100–119
224–243
144
ppOX (5)
(data from [17])
NM_001524.1 S
A
CACAATTGACAGCCTCAAGG
AATGGAGACTCGTCTTTATT
1–20
558–577
576
OXR1 (6) NM_001525.2 S
A
CAACAGGTTCTTGGTGAAG
TCAGCCTCAAACTTCCTTA
177–195
240–258
82
OXR1 (7) NM_001525.2 S
A
TGTTCCGCCAAGCCAGTGACC
AGCATCGGCTCTGCAAGGAC
1362–1382
1585–1604
243
OXR1 (8)  
(data from [17])
NM_001525.2 S
A
TATGTGGCTGTGTTCGTCGT
CCCAGCGTTCATCACAGAC
542–561
986–1004
463
OXR1 (9) Commercially available PPH01112A primers (SABiosciencescompany, Qiagen), 
sequences unknown
OXR2 (10) NM_001526.3 S
A
CCAATAGTGCTGCGAATCC
AGTTGCTGATTTGAGTGGTC
1379–1397
1536–1555
177
OXR2 (11) NM_001526.3 S
A
GGCTGAAATAAAGCAGATCCG
AGGTAAACCAGGCATACACA
1185–1205 
1338–1357
173
GAPDH NM_001289746.1 S
A
GAAGGTGAAGGTCGGAGTCA
GACAAGCTTCCCGTTCTCAG
180–199
359–378
199
Oligonucleotide sequences for different sense (S) and antisense (A) primers are shown. ppOX primer No. 5 and OXR1 primer No. 8 were used in 
[17, 18]. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was the reference gene
Table 2. Efficiency, R2 (coefficient of correlation obtained 
for the standard curve) and LOD (limit of detection) for 
selected primers identified on agarose gel as a positive 
control (human placenta and adrenal gland)
Primers Efficiency R2 LOD [ng/µL]
ppOX (1) 1.877 0.998 19.0 × 10–8
OXR1 (7) 1.931 0.996 15.5 × 10–17
OXR2 (11) 1.859 0.998 17.6 × 10–18
GAPDH 1.860 0.980 13.8 × 10–10
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(×10,000 concentrate in DMSO) (Lonza, Rockland, ME, 
USA). This is a highly sensitive fluorescent stain for detecting 
DNA and RNA. To each probe the 6xOrange Loading dye 
was added (Thermo Scientific). The O’range ruler (50 kb) 
(Thermo Scientific) was used as a size marker. In this system 
size differences between products are notable and such 
products are easy to recognize on 2% agarose gel.
Results
The expression analysis of the studied genes was 
performed using conventional PCR and QPCR. In all 
studied human prostatic cell lines (LNCaP; Du145; 
PC3; PrEC; PrSmC and PrSc) we were unable to 
demonstrate expression of ppOX with primers 1–4 
(Table 1), while such products were found in posi-
tive control tissue (human placenta) (Figure 1). Of 
importance is that in all studied prostatic cell lines 
as well as in human placenta no reaction products 
were observed with primer No. 5 (Table 1), and in 
this case analysis of melting temperatures revealed 
no amplification products (Figure 2A).
Expression of the OXR1 gene was studied with 
the use of 4 primers (Table 1). In all studied human 
prostatic cell lines with primers No. 6 and 7 (Table 1) 
amplifications products were not found; however, 
they were observed in positive control tissue (human 
adrenal gland) (Figure 1). On the other hand, with 
primer No. 8 (Table 1) strips were observed in all 
studied cell lines and in positive control tissue (Fig-
ure 1). However, the size of the obtained products 
was less than 50 bp and their melting points were 
very low, approximately 79°C (Figure 2B). We also 
studied expression of OXR1 with commercially avail-
able primers (No. 9, Table 1). As shown in Figure 3, 
reaction products with the size of approximately 100 bp 
were observed in studied human prostatic cell lines as 
well as in negative controls (–RT). Thus, the obtained 
results were false positive. As seen in Figure 2C and D, 
melting temperatures of products obtained with 
these primers were the same (84°C) in the studied 
human prostatic cell lines as well as in negative con-
trols (–RT).
Expression of the OXR2 gene was studied with 
2 primers (primers 10 and 11, Table 1). In all studied 
human prostatic cell lines amplifications products were 
not found, however, they were observed in positive 
control tissue (human adrenal gland) (Figure 1). In 
positive control tissue melting temperatures of the ob-
tained products were the same (85.5°C) (Figure 2E). 
As it follows from data shown in Table 2, for 
selected primers (ppOX (1); OXR1 (7); OXR2 (11) 
and GADPH) efficiencies and R2 values were very 
high and were within the recommended ranges for 
QPCR assays. As revealed by dilution experiments, 
the lowest LOD values were obtained for OXR1 (7) 
and OXR2 (11) primers.
Discussion
Studies on the expression of OXs and their receptors 
in human prostate gland and human prostatic cell lines 
are scanty and their results contradictory. Moreover, 
most relevant data were obtained by means of immuno-
histochemistry (IHC); however, many of the currently 
available antisera can produce nonspecific stain- 
ing [7]. It should be emphasized, that as it follows from 
numerous studies, IHC staining is not in itself a proof 
Figure 1. Electrophoretic analysis of RT-PCR products  
on agarose gel in examined human prostatic cell lines.  
1 — marker O’rangeruller (50 kb); 2 — LNCaP line;  
3 — Du145 line; 4 — PC3 line; 5 — PrEC line; 6 — PrSmC 
line; 7 — PrSc line; 8 — positive control tissues (for ppOX 
— human placenta, for OXR1 and OXR2 — human adrenal 
gland). ppOX — analysis with primers No. 1 from the Table 1; 
OXR1 — primers No. 7 from the Table 1; OXR2 — primers 
No. 10 from the Table 1; GAPDH — the reference gene, 
and OXR1 (dimers) — primers No. 8 from the Table 1  
— dimers are visible in each sample, even positive control. 
Negative controls (–RT of the RNA) are not shown
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Figure 2. Melting curves (dissociation curves) of QPCR analyses of human ppOX, OXR1 and OXR2. A. ppOX (primers 
No. 5 from the Table 1) — no amplification products; B. OXR1 (primers No. 8 from the Table 1) — dimers, with very low 
melting temperature; C. OXR1 in human prostatic cultured cells (primers PPH01112A, SABiosciences — from Figure 3); 
D. OXR1 negative control –RT (primers PPH01112A SABiosciences — from Figure 3); E. OXR2 in positive control  
— human adrenal gland (primer No. 10 from the Table 1). All PCR reactions were performed in duplicates
B
C
D
E
A
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of expression of the studied compound and should be 
confirmed by more precise methods [24–27].
Earlier reports on the male reproductive system con-
tained no data on expression of the ppOX–OXRs system 
in the prostate gland [9, 11–14]. To our knowledge, 
Nakabayashi et al. [28] were the first to report the ab-
sence of OXA-like immunoreactivity (LI) in the human 
prostate. The expression of genes coding for ppOX in 
the urethroprostatic complex of cattle was demonstrated 
by PCR and Western blot, and IHC revealed OXA-LI 
substances in the exocrine epithelium of the gland [15]. 
On the other hand, in our earlier QPCR study we were 
unable to demonstrate expression of ppOX in human 
normal and hyperplastic prostate [16]. Likewise, in our 
recent microarray study (Human Obesity RT2 Profiler 
PCR Array, Qiagen) we were unable to demonstrate 
expression of ppOX in both normal human prostate 
gland and benign prostate hyperplasia [29].
Recently, three reports have published data on 
the presence of OXA-LI in normal human prostate, 
BPH and in prostate cancer (PC) [17, 18, 30]. In two 
of them IHC reaction products for ppOX and OXA 
were observed in the epithelium of human normal 
and hyperplastic prostatic glands and the presence 
of ppOX protein was confirmed by Western blot-
ting. The French group, on the other hand, observed 
OXA-LI in ‘fiber-like’ structures of the stroma and 
no reaction was observed in cancerous foci of PC [30]. 
Moreover, Valiante et al. [17, 18] demonstrated also 
expression of ppOX by means of RT-PCR. In light 
of these discrepancies we performed studies on the 
expression of ppOX in 6 human prostatic cell lines 
— LNCaP; Du145; PC3; PrEC; PrSmC and PrSc. 
Interestingly, with the four carefully designed primer 
pairs, in all studied cell lines we failed to demonstrate 
expression of ppOX. 
In an attempt to solve the above mentioned 
discrepancies on the expression of ppOX in human 
prostate and prostatic cell lines, we had analyzed 
RT-PCR method applied in [17, 18]. To our surprise, 
in studies on human prostate glands authors used rat 
brain as a positive control tissue. As it follows from 
the analysis of primers, the human ppOX primers are 
unable to amplify rat ppOX, since there is no 100% 
homology between human and rat sequences: the left 
primer of ppOX has only 8 of 20 nucleotides homology 
to rat sequence, whereas the right primer — 15 of 
20 nucleotides (Figure 4A). In our hands these primers 
failed to give positive results. Moreover, analysis of 
melting temperatures of these primers revealed no 
amplification products. Thus, the findings of Val-
iante et al. [17, 18] on the presence of ppOX mRNA 
in human normal and hyperplastic prostate glands 
and PC seem to be doubtful. It should be pointed 
out that in both reports authors applied the same 
primers, however, the obtained amplicons differed 
substantially in length (576 bp in [17] and 393 bp in 
[18]) and such different amplicons were also identified 
in homogenates of the rat brain.
Only scanty data are available on expression of 
OXRs in human prostatic cell lines. The expression 
of OXR1 was detected in human normal prostate 
epithelium immortalized cells PNT1A by means 
of the Western blot technique [17]. In subsequent 
report this group demonstrated also the presence 
of OXR1 mRNA in LNCaP cell line [18]. However, 
other authors, identified by means of QPCR, the 
presence of OXR1 mRNA in Du145 but not LNCaP 
cell line [30]. It has to be emphasized that induction of 
a neuroendocrine differentiation resulted in a highly 
significant increase of OX1R mRNA expression in 
Du145 cells while no such effect was observed in 
LNCaP cell line [30].
In the present studies, with 4 different primer pairs 
we failed to demonstrate expression of both OXR1 
and OXR2 in all studied human prostatic cell lines — 
LNCaP; Du145; PC3; PrEC; PrSmC and PrSc, while 
reaction products were observed in positive control 
tissue (human adrenal gland). The above reported 
divergences in the expression of OXRs in prostate 
and human prostatic cell lines prompted us to ana-
lyses the details of QPCR methods, on basis of which 
positive results have been reported. Like in the case 
of ppOX, in studies of Valiante et al. [18] on human 
prostate glands and cell lines authors used rat brain 
as a positive control tissue. Again, analysis of primers 
for OXR1 shows that the human primers are unable to 
amplify rat OXR1, since there is no 100% homology 
between human and rat sequences — the left primer 
of OXR1 has only 15 of 20 nucleotides homology to rat 
Figure 3. Ethidium bromide-stained 2% agarose gel sho-
wing human prostatic cell lines cDNA (lines 2–5) and –RT 
negative control (lines 6–7) amplified with commercially 
available human orexin receptor 1 (OXR1) primers  
(No. 9 in the Table 1, SABiosciences). Note the presence 
of reaction products with the size of approximately 100 bp. 
Line 1 — marker O’rangeruller (50 kb)
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Figure 4. An outline of genes and primers used in [17], shown in arrows, for demonstration of (A) human ppOX (No. 5 in the 
Table 1) and (B) OXR1 (No. 8 in the Table 1) and their alignment with rat sequences. As seen, binding of primers used for 
studies of rat tissues are not identical with human cDNA fragments. Homologous nucleotides on a gray background
sequence, whereas the right primer — 18 of 19 nucle-
otides (Figure 4B). In our hands, with these primers 
reaction products were observed both in all studied 
prostatic cell lines and positive control tissue. How-
ever, the low size of the obtained products (< 50 bp) 
and their very low melting points (ca 79°C) suggest 
that observed products were primer dimers. Thus, re-
ported data on expression of OXR1 in normal human 
prostate, BPH and PC again are doubtful.
To validate the obtained results in an another manner, 
we used commercially available primers, which, how-
ever, yielded false positive results: with ‘PPH01112A 
for human HCRTR1’ primer, reaction products of 
the size of approximately 100 bp were observed in all 
studied human prostatic cell lines as well as in negative 
controls (–RT). Therefore, we are not surprised by 
results obtained by means of Human Obesity RT2 
Profiler PCR Array (SuperArrayBioscience; SABi-
oscience) applied by us in studies on OXR1 expres-
sion in normal human prostate and benign prostate 
hyperplasia [29]. In these studies we demonstrated 
reaction products for OXR1; however, the primers 
applied were the same, as purchased for the present 
study. Furthermore, the size of products (for OXR1) 
demonstrated with the same primers and shown in 
both publications [17, 18] differed significantly (463 bp 
vs. 356 bp). And again, the same primers give positive 
reaction with the homogenates of rat brain, which had 
been used as a control tissue.
In a recent study expression of the OXR1 gene in 
the human androgen-dependent prostate carcinoma 
cells LNCaP was found to be very low (mean Ct value 
ca 34) and expression of the gene was stimulated 
by 25% by the addition of OXA [18]. However, the 
primers, applied by the authors, span only one exon 
which does not allow differentiating whether reaction 
product originates from cDNA or from genomic DNA 
contaminations. It was reported that samples were 
digested with DNase [18], but in case of one exon- 
-spanning primers it would be desirable to present 
also results of negative reactions (–RT).
It has to be mentioned that results of the immu-
nohistochemical studies regarding the presence of 
OXRs in human prostate and prostatic cell lines are 
also controversial, mainly due to the various specific-
ity of applied antibodies. Some of them are directed 
against both OXR1 and OXR2, while others are more 
specific. In this regard OXR1-LI cells were described 
in cattle urethroprostatic complex in which expression 
of OXR1 gene was confirmed by RT-PCR and West-
B
A
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ern blot [15]. OXR2-LI, on the other hand was found 
in epithelial and smooth muscle cells of the stroma 
as well as in neutrophils in normal and hyperplastic 
human prostate [16]. In these studies, expression of 
OXR2, but not OXR1 was confirmed by means of 
QPCR [16]. Subsequently, OXR1/2-LI was described 
in the epithelium of normal human prostate as well 
as in prostate cancer, these data, however, were not 
confirmed by RT-PCR [31]. OXR1-LI substances 
were also found in the cytoplasm of epithelial cells of 
normal and hyperplastic prostates [17]. In their studies 
expression of OXR1 was also checked by QPCR and 
authors claim that it is specific reaction, although 
doubtful primers were used. Recently, OXR1- and 
OXR2-LI were studied in BPH and PC [30]. OXR1- 
-LI substances in BPH were observed only in scattered 
cells of few acini while in low and medium grade 
PC, some cancerous foci contained cells positive for 
OXR1. In high grade PC adenocarcinomatous forma-
tions were intensively stained for OXR1, while OXR2 
was only detected in a few cancer cells. 
Thus, as it follows from the above discussion, the 
presence of ppOX and orexin receptors mRNAs in 
human normal prostate gland, BPH and prostate 
cancer, as well as in human prostatic cell lines is very 
controversial. These discrepancies primarily seem to 
arise from imperfect methodology, in which careful 
construction of primers and application of numerous 
control systems, taking into account the species-relat-
ed differences, is the most important. As we revealed, 
even commercially available primers, may not be fully 
reliable, and this notion may hold true also for other 
types of tissues and cells.
The reported discrepancies on the expression of 
ppOX–OXRs system in human prostate may also 
depend on studied materials. OXR1 is reported to 
be overexpressed in advanced prostate cancer with 
a neuroendocrine differentiation [30]. Furthermore, 
acquisition of a neuroendocrine phenotype by the 
Du145 cells is also associated with an overexpression 
of OX1R [30]. Thus, transformation of prostatic can-
cerous cells into neuroendocrine cells may profoundly 
change expression of various genes.
The other source of discrepancies observed in 
expression of ppOX–OXRs system in human prostate 
may arise from the presence of blood cells present in 
prostate samples. As reported in the studies on normal 
and hyperplastic human prostate in which OXR2-LI 
was found in epithelial and smooth muscle cells of the 
stroma as well as neutrophils, expression of OXR2, 
but not OXR1 was confirmed by means of QPCR [16]. 
Expression of OXR2 in neutrophils was reported in 
many studies [e.g. 32–34], and it should be noted that 
in immunology OXR2 is usually described as CD200R1 
(http://www.ncbi.nlm.nih.gov/gene/131450).
Conclusions
In conclusion, our thorough studies revealed no evi-
dence of preproorexin–orexin receptors system gene 
expression in human prostate cell lines. Available data 
suggest that all to date found premises for these genes 
system expression in normal prostate, benign pros-
tatic hyperplasia, prostate cancer and prostatic cell 
lines may have arisen from either non-prostate cells 
included in the samples or from faulty PCR settings.
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